In order to respond to the outbreak of pneumonia caused by a novel coronavirus COVID-19, global scientific research institutions and pharmaceutical companies are stepping up related vaccine development and antiviral drug trials. Scientists from multiple countries are working hard to identify drug candidates that can be used for clinical therapy to patients with 2019-nCoV infected pneumonia by screening compound libraries.
TargetMol as a drug screen expert quickly generated this compound library by carefully selecting 223 compounds that have been demonstrated to have anti-coronavirus activity and some of them are broad-spectrum antiviral agents including Lopinavir/Ritonavir, Chloroquine diphosphate (combination use with Remdesivir), Polydatin (bind with Mpro), etc. We also will keep updating it in response to the newest research progress.
|100 μL * 10 mM (in DMSO)||USD 3495.00|
|250 μL * 10 mM (in DMSO)||USD 5770.00|
|1 mg||USD 5770.00|
The compound library can be highly customized. You can select compounds, quantities, format (dry/solid or DMSO), plate map, and concentration to meet your specific requirement. Please check our Compound Library Instructions for more information.